胸腺肽
医学
放射治疗
免疫系统
内科学
肺癌
养生
免疫抑制
安慰剂
淋巴细胞
胃肠病学
免疫学
肿瘤科
病理
替代医学
作者
Richard S. Schulof,Margaret Lloyd,Patricia A. Cleary,Susan R. Palaszynski,Dongmei Mai,Joanna Cox,Oliver Alabaster,Alan Goldstein
出处
期刊:PubMed
日期:1985-04-01
卷期号:4 (2): 147-58
被引量:31
摘要
A randomized trial was performed in 42 postradiotherapy patients with non-small cell lung cancer to determine whether the administration of synthetic thymosin-alpha 1 by either a loading dose or a twice-weekly schedule could accelerate the reconstitution of thymic dependent immunity. The radiotherapy-induced immunosuppression was characterized by an absolute T cell lymphopenia and by impaired T cell function in lymphoproliferative assays. Placebo-treated patients did not show any improvement in T cell numbers or function over 15 weeks of serial immune monitoring, and exhibited gradual depressions of helper T lymphocyte percentages. Patients treated with thymosin by the loading dose regimen exhibited a normalization of T cell function (p = 0.04), whereas patients treated with the twice-weekly schedule maintained normal helper T cell percentages (p = 0.04). Thymosin treatment was associated with significant improvements in relapse-free and overall survival, which was most pronounced for patients with nonbulky tumors. Thymosin-alpha 1 exhibits schedule-dependent immune restorative and homeostatic properties. Large scale Phase III trials are indicated to definitively establish the impact of thymosin therapy in lung cancer patients treated with radiotherapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI